Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Core Insights - Biomerica, Inc. reported a 5% year-over-year increase in total revenue for the second quarter of fiscal 2025, achieving sustained revenue growth, improved gross margins, and significant cost savings [1][4]. Financial Performance - For the fiscal second quarter of 2025, Biomerica reported net sales of $1.64 million, up from$1.57 million in the same quarter of the previous year, indicating a 5% growth driven by demand from both new and existing customers [5]. - Gross margins improved from 21% in Q2 FY2024 to 27% in Q2 FY2025, attributed to a favorable sales mix and reduced direct labor costs [7]. - Operating expenses decreased by 26% year-over-year to $1.43 million, down from$1.93 million, due to efficiencies from workforce reductions and streamlined operations [7]. - The operating loss decreased by 39% to $990,000 from$1.6 million, while the net loss reduced by 37% to $950,000 from$1.5 million, reflecting strategic cost savings and operational enhancements [8]. Product Development and Market Opportunities - The company launched the inFoods IBS test, allowing patients to order the test directly online, which identifies trigger foods causing IBS symptoms [2]. - Biomerica secured three key patents for inFoods technology, addressing multi-billion-dollar market opportunities in GERD ($4.0 billion+), Crohn's Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) [2]. - The company is expanding distribution partnerships in the U.S. and internationally to broaden the availability of inFoods IBS [3]. Strategic Focus - The CEO emphasized the company's commitment to achieving cash flow break-even and pursuing near-term opportunities to enhance financial performance [10].